Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

MDS 2023 | Unmet needs in aplastic anemia: dealing with severe infections & managing elderly patients

Austin Kulasekararaj • 5 May 2023

MDS 2023

Anemias Aplastic Anemia Cyclosporine Eltrombopag Horse antithymocyte globulin

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, outlines two difficult-to-treat patient groups in aplastic anemia – those who present with acute infections, and older patients who do not tolerate standard therapies. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Aplastic anemia updates: RACE, the role of anabolic steroids, clonal architecture & more

Austin Kulasekararaj • 5 May 2023

Promising doublets under investigation in clinical trials in 1L intermediate- and high-risk MDS

Austin Kulasekararaj • 5 May 2023

Benefits, applicability & uses of the IPSS-M in MDS

Austin Kulasekararaj • 5 May 2023

Strategies to overcome azacitidine resistance in MDS: combination strategies & mutation analysis

Austin Kulasekararaj • 5 May 2023

Related Videos

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

A two-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia

Antonio Risitano • 16 Apr 2024

Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency

Hanny Al-Samkari • 9 Dec 2023

SATISFY: mitapivat in patients with erythrocyte membranopathies

Kevin Kuo • 10 Dec 2023